MPH formulation | Synonyms | Product availability | Modified-release technology | Immediate-release: extended-release ratio (%) | Duration of actiona |
---|---|---|---|---|---|
Biphentin® [10] | MPH ER | Canada | Multilayer-release (MLR) bead formulation | 40:60 | Not stated: biphasic delivery profile |
Concerta® [12] | Concerta extended release; Concerta® LP; methylphenidate hydrochloride; OROS MPH | Africab, Asiac, Australia, Europed, New Zealand, North Americae, South Americaf | OROS® (Osmotic Release Oral System) | 22:78 | 12 hours |
Daytrana® [13] | MPH transdermal system; MethyPatch; MTS | USA | Transdermal patch | Continuous delivery | 9 hours |
Equasym XL® [11] | Equasym Depot®; Equasym Retard®, Equasym XR®, Quasym LP®; Metadate CD®; Metadate ER® | Europeg, South Korea, USA | Diffucaps® | 30:70 | 8 hours |
Focalin XR® [7] | d-MPH-ER | Switzerland, USAh | SODAS® (Spheroidal Oral Drug Absorption System) | 50:50 | Not stated: two distinct peaks approximately 4 hours apart |
Medikinet® retard [9] | Medikinet®; Medikinet® CR; Medikinet® EM; Medikinet® MR; Medikinet® XL | Europei, Israel, Korea, South Americaj | Modified-release capsules | 50:50 | 8 hours |
Ritalin LA® [6] | Ritalin LP®; Miacalcic | France, Chile, USAh | SODAS® (Spheroidal Oral Drug Absorption System) | 50:50 | Not stated: two distinct peaks approximately 4 hours apart |
Ritalin SR® [5] | n/a | Canada, USAh | Wax matrix | Continuous release | 8 hours |